Biofrontera closes acquisition of U.S. rights to Ameluz; raises $2.5M in Series C preferred

Biofrontera Inc.

Acquired all U.S. rights to Ameluz and RhodoLED from former parent Biofrontera AG per Asset Purchase Agreement dated Oct 20, 2025.
Earnout replaces prior transfer pricing model: 12% of U.S. net sales ≤$65M, 15% if >$65M.
Closed second tranche of Series C Preferred Stock, raising $2.5M gross; total offering now $11M.
Believes stockholders' equity now exceeds $5M, regaining compliance with Nasdaq minimum equity requirement.
Proceeds from preferred stock to fund acquisition and transfer costs and general corporate purposes.

item 1.01 item 2.01 item 3.02 item 8.01 item 5.03 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.